RedHill Biopharma (RDHL) has released an update.
RedHill Biopharma Ltd. has mutually agreed with Cosmo Technologies Ltd. to terminate their exclusive U.S. license agreement for Aemcolo, a traveler’s diarrhea treatment. The termination will come into effect on October 8, 2024, resulting in all rights returning to Cosmo, and RedHill ceasing its commercialization of the drug. RedHill, a specialty biopharmaceutical company, is known for its focus on gastrointestinal and infectious diseases, with several late-stage development programs underway.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
